Overview
To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).
Eligibility
Inclusion Criteria:
- Women or men age >18 years
- Diagnosed with stage I-III breast cancer prescribed endocrine therapy
- Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation)
- Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention
- Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire
Exclusion Criteria:
- Evidence of breast cancer recurrence
- Non-English or Non-Spanish speaking
- Not cognitively able to complete study requirements
- Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR
- Inability to provide informed consent